TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03721016
Drug: MT10109L
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Study: NCT03721016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Study: NCT03686813
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04148937
Drug: LY3475070
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00254163
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00979927
Drug: SPC3649
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 weekly doses
Study: NCT01581060
Drug: WX-554
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of WX-554
Study: NCT00524043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 6 weeks
Study: NCT03381625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
Study: NCT02125630
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy based on tumor phenotype
Study: NCT02117401
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
Study: NCT02232178
Drug: 2 100mg Xaracoll implants
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02232178
Drug: 3 100mg Xaracoll implants
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00929591
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00929591
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00929591
Drug: endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02463318
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin is used for healthy subjects and multiple sclerosis patients
Study: NCT00929591
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00952393
Drug: Pharmacokinetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
Study: NCT01902121
Drug: Technosphere® Insulin 10U + 20U
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Insulin
Study: NCT01902121
Drug: Technosphere® Insulin 30U
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Insulin
Study: NCT00769912
Drug: 50% N2O- 50%O2 mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% N2O- 50%O2 mixture administration
Study: NCT00957086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
Study: NCT02210260
Drug: Diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mcg
Study: NCT02668952
Drug: 0.9% Normal Saline (0.9% Sodium Chloride) injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00074542
Drug: Epanova™ (Omega-3 Free Fatty Acids)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03358004
Drug: Capecitabine 500 MG
Normalized name: capecitabine 500 MG
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
Study: NCT01224106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Placebo SC injection Q4W.
Study: NCT02019758
Drug: Placebo inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler - 4 puffs twice daily
Study: NCT00446797
Drug: Non-selective NSAIDS
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective NSAIDs administered at usual (standard) doses.
Study: NCT00446797
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
Study: NCT00685113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal ring inserted vaginally and replaced every 4 weeks
Study: NCT01735240
Drug: AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5069 15 mg (3x5 mg capsules) single administration
Study: NCT04147416
Drug: HSK3486 0.1-0.2 /0.3 mg / kg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
Study: NCT00319254
Drug: SKI-606 (Bosutinib)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
Study: NCT03635112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
Study: NCT02412020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01234311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00848783
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05525065
Drug: GlucoCorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid as calculated in prednisone oral equivalents.
Study: NCT01829867
Drug: sNN0031
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877811
Drug: RXDX-105
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment.
Study: NCT02527564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01773187
Drug: Best Available Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02637648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: parallel Group administration
Study: NCT01712204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule BID for 16 Weeks
Study: NCT02345213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be orally administered once daily after breakfast
Study: NCT01720446
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
Study: NCT00064636
Drug: VELCADE TM (bortezomib) for Injection, or PS-341
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03644667
Drug: Standard of Care Triple IS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care triple maintenance IS includes:~1. A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~   Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~2. An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~   Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~3. Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol.
Study: NCT03778502
Drug: Direct Oral Anticoagulants
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
Study: NCT02315534
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide.
Study: NCT02452424
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX3397 capsules, 200 mg
Study: NCT00103740
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg zoledronic acid in 5 mL of sterile water for infusion
Study: NCT00103740
Drug: placebo to zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mL of sterile water for infusion
Study: NCT00103740
Drug: Placebo to risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT02212080
Drug: BAY1214784
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
Study: NCT02212080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
Study: NCT00103740
Drug: Calcium and vitamin D supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium and vitamin D supplements were supplied
Study: NCT02503150
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
Study: NCT00525005
Drug: DOS (Docetaxel, Oxaliplatin and S-1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
Study: NCT03363165
Drug: VM202
Normalized name: Vascular Endothelial Growth Factor 2 Plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD.
Study: NCT00006133
Drug: estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02623491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo.
Study: NCT01876511
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 10 mg/kg every 14 days
Study: NCT00604006
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablets (placed in capsules for blinding) once daily.
Study: NCT00604006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose in capsules for blinding) once daily
Study: NCT02255760
Drug: MEDI3902 - Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
Study: NCT02255760
Drug: MEDI3902 - Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
Study: NCT02255760
Drug: MEDI3902 - Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
Study: NCT02255760
Drug: MEDI3902 - Dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
Study: NCT00003838
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV MTX on days +1, +3, and +6 will be given
Study: NCT00020124
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03801226
Drug: Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
Study: NCT00973141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
Study: NCT00201695
Drug: Doxil®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 IV day 1
Study: NCT00169156
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 D1
Study: NCT02145182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride
Study: NCT00158873
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02111148
Drug: 5ml saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: the vagina will be washed with 5ml saline and vaginal wash will be collected.
Study: NCT03172533
Drug: ethinyl estradiol 0.03mg and dienogest 2 mg (combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: approved oral contraceptive (Germany): Maxim
Study: NCT03172533
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00158873
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00217191
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04331054
Drug: 2: Usual practice + SYMBICORT RAPIHALER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs bid during 30 days by inhalation
Study: NCT03001128
Drug: Antiretroviral treatment pause
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment pause
Study: NCT01574651
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
Study: NCT01574651
Drug: Placebo to QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
Study: NCT02134470
Drug: Testosterone supplementation
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
Study: NCT04581967
Drug: Doxorubicin-Cyclophosphamide regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
Study: NCT00264537
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injections
Study: NCT00264537
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
Study: NCT00264537
Drug: Methotrexate capsules
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
Study: NCT03790059
Drug: H101
Normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
Study: NCT00636285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00636285
Drug: BSYX-A110
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSYX-A110, Dosed intravenously, 3 mg/kg
Study: NCT00636285
Drug: BSYX-A110
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSYX-A110, Dosed intravenously, 10 mg/kg
Study: NCT00853151
Drug: LY2428757
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg subcutaneous injection 1 time a week for 5 weeks
Study: NCT00853151
Drug: Placebo for LY2428757
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection 1 time a week for 5 weeks
Study: NCT00853151
Drug: Placebo for TT223
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection once a day for 4 weeks
Study: NCT02221232
Drug: ZuraPrep
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT02221232
Drug: ZuraPrep Vehicle
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT01504412
Drug: DS-5565
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered twice daily
Study: NCT01504412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
Study: NCT03607123
Drug: Anti arryhthmic drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
Study: NCT01338129
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT04004429
Drug: 50 mg AP1189
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg AP1189 powder in bottle
Study: NCT04004429
Drug: AP1189
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg AP1189 powder in bottle
Study: NCT04004429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder in bottle
Study: NCT00631189
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg oral
Study: NCT00631189
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg oral
Study: NCT02135549
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT04611061
Drug: Kagocel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Study: NCT04611061
Drug: No one
Normalized name: ALCOHOL 70 g in 100 mL TOPICAL GEL [d.therapino one step hand sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
Study: NCT00117299
Drug: PTK787/ZK222584
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
Study: NCT01520350
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03199417
Drug: Multiprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
Study: NCT01063829
Drug: 60 mg AIC246
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01063829
Drug: 120 mg AIC246
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01063829
Drug: 240 mg AIC246
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00134017
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -3, -2, +3, +4: 50 mg/kg IV daily
Study: NCT02862327
Drug: intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection of placebo
Study: NCT04304534
Drug: BAY2433334
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, taken orally once a day.